Breaking News Instant updates and real-time market news.

CANF

Can-Fite BioPharma

$2.98

-0.05 (-1.65%)

07:09
06/03/19
06/03
07:09
06/03/19
07:09

Can-Fite says Phase II liver cancer study did not meet primary endpoint

Can-Fite BioPharma announced that data from its recently completed Phase II trial in patients with hepatocellular cancer, the most common form of liver cancer, was presented at the late-breaking abstract session of the 54th Annual Meeting of the American Society of Clinical Oncology. Prof. Salomon M. Stemmer, Principal Investigator of Can-Fite's Phase II trial, delivered the presentation on Sunday June 2, 2019 at the Developmental Immunotherapy and Tumor Immunobiology session. The presentation is entitled: "A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson, an a3 adenosine receptor agonist, as a second-line treatment in patients with Child-Pugh B advanced hepatocellular carcinoma." While the Phase II study did not achieve its primary endpoint of overall survival in the whole population, superiority in overall survival was found in the largest study subpopulation of patients who were classified Child Pugh B7, based on severity of disease compared to the placebo treated group. Median survival in the Namodenoson group was 6.8 months, versus 4.3 months for the placebo group. The "most impressive" finding was that 44% of the patients with Child Pugh B7 treated with Namodenoson were alive at one year compared to 18% in the placebo group. In the overall patient population, among patients who had at least one assessment post baseline, disease control was significant in the Namodenoson group, 26% versus 10% in the control group after four months of treatment, P value 0.013. Among the other positive findings that were presented is the 9% partial response in the Namodenoson treated group vs. 0% in the placebo group. An example of a patient demonstrating an excellent tumor shrinkage was presented. A3AR expression level at baseline was 1.98+/-0.36 in comparison to 1 unit in healthy subjects and was not changed substantially during the treatment period, demonstrating that continuous treatment with Namodenoson does not result in de-sensitization or loss of the target. Consistent with its previously demonstrated favorable safety profile, Namodenoson showed an adverse event profile that was comparable to that of placebo.

CANF Can-Fite BioPharma
$2.98

-0.05 (-1.65%)

06/13/18
HCWC
06/13/18
INITIATION
Target $8
HCWC
Buy
Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert assumed coverage of Can-Fite BioPharma with a Buy rating and $8 price target. The analyst believes the company's adenosine receptor's differential expression levels make it a good target for drug development in autoimmune disease and cancer.
06/13/18
06/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) initiated with a Sell at Berenberg. 2. Emergent BioSolutions (EBS) initiated with a Buy at Argus. 3. Nine Energy Services (NINE) initiated with a Strong Buy at Raymond James. 4. Can-Fite BioPharma (CANF) assumed with a Buy at H.C. Wainwright. 5. Control4 (CTRL) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/18
HCWC
10/31/18
NO CHANGE
HCWC
Buy
H.C. Wainwright 'cautiously optimistic' about Can-Fite after trial results delay
After Can-Fite BioPharma announced earlier today that top line efficacy results are now expected during the first quarter of 2019 in its Phase 2 clinical trial of drug candidate Namodenoson for the treatment of advanced hepatocellular carcinoma due to patient survival, H.C. Wainwright analyst Jason Kolbert said he is "cautiously optimistic" given that he finds it surprising that the trial has gone on this long. His understanding is that a six week or bigger difference between the active and control arms is considered clinically meaningful in this indication, adding that if the data is strong enough the trial is could be used as a registrational study given the unmet medical need. He keeps a Buy rating on Can-Fite shares, which were down 5% in morning trading.
03/27/19
HCWC
03/27/19
NO CHANGE
Target $3
HCWC
Buy
Can-Fite selloff yesterday on trial miss unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino recommends Can-Fite BioPharma shares, especially on weakness, based on expectations for positive catalysts with piclidenoson in 2019. The company yesterday announced that its Phase 2 study with namodenoson in hepatocellular carcinoma did not achieve its primary endpoint of overall survival. The analyst, however, did not have this indication in his model and thinks the stock pullback yesterday is unwarranted. He recommends Can-Fite shares based on the potential for second half of 2019 data readouts from Phase 3 studies with its lead candidate piclidenoson in rheumatoid arthritis and psoriasis to be positive. Bernardino reiterates a Buy rating on Can-Fite BioPharma with a $3 price target. The stock closed yesterday down 28%, or 36c, to 93c.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$45.88

0.88 (1.96%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
Breaking Hot Stocks news story on E-Trade, Charles Schwab, TD Ameritrade »

E-Trade drops 16c to…

ETFC

E-Trade

$45.88

0.88 (1.96%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

KKR

KKR

$29.32

0.21 (0.72%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
KKR to sell LGC to consortium led by Cinven and Astorg, terms not disclosed »

KKR announces it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

, AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
Breaking Hot Stocks news story on Charles Schwab, TD Ameritrade »

Charles Schwab drops 1%…

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:42
11/21/19
11/21
05:42
11/21/19
05:42
Hot Stocks
Breaking Hot Stocks news story on TD Ameritrade, Charles Schwab »

TD Ameritrade jumps 13%…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:41
11/21/19
11/21
05:41
11/21/19
05:41
Periodicals
Charles Schwab in talks to acquire TD Ameritrade, CNBC reports »

Charles Schwab (SCHW) is…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$189.85

7.64 (4.19%)

05:40
11/21/19
11/21
05:40
11/21/19
05:40
Downgrade
RH rating change  »

RH downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$8.62

-0.03 (-0.35%)

05:39
11/21/19
11/21
05:39
11/21/19
05:39
Downgrade
MacroGenics rating change  »

MacroGenics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

HARP

Harpoon Therapeutics

$14.50

-0.22 (-1.49%)

, ABBV

AbbVie

$87.20

-1.82 (-2.04%)

05:38
11/21/19
11/21
05:38
11/21/19
05:38
Hot Stocks
Harpoon Therapeutics, AbbVie announce licensing, option collaboration »

Harpoon Therapeutics…

HARP

Harpoon Therapeutics

$14.50

-0.22 (-1.49%)

ABBV

AbbVie

$87.20

-1.82 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

THDDY

TV Asahi

$0.00

(0.00%)

05:38
11/21/19
11/21
05:38
11/21/19
05:38
Downgrade
TV Asahi rating change  »

TV Asahi downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

05:37
11/21/19
11/21
05:37
11/21/19
05:37
Downgrade
Nintendo rating change  »

Nintendo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$43.49

-0.33 (-0.75%)

05:36
11/21/19
11/21
05:36
11/21/19
05:36
Earnings
Breaking Earnings news story on Baozun »

Baozun sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SGSOY

SGS SA

$0.00

(0.00%)

05:36
11/21/19
11/21
05:36
11/21/19
05:36
Upgrade
SGS SA rating change  »

SGS SA upgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$43.49

-0.33 (-0.75%)

05:35
11/21/19
11/21
05:35
11/21/19
05:35
Earnings
Baozun reports Q3 EPS 14c, consensus 14c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FUJHY

Subaru

$0.00

(0.00%)

05:35
11/21/19
11/21
05:35
11/21/19
05:35
Downgrade
Subaru rating change  »

Subaru downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$55.27

-0.98 (-1.74%)

05:34
11/21/19
11/21
05:34
11/21/19
05:34
Initiation
Dell Technologies initiated  »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 09

    Dec

  • 09

    Dec

PCG

PG&E

$7.14

0.29 (4.23%)

05:34
11/21/19
11/21
05:34
11/21/19
05:34
Hot Stocks
PG&E begins restoring power in Napa, Sonoma counties »

As of 7 p.m., Pacific Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

DRTGF

Dart Group

$0.00

(0.00%)

05:33
11/21/19
11/21
05:33
11/21/19
05:33
Upgrade
Dart Group rating change  »

Dart Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$2.91

-0.06 (-2.02%)

05:32
11/21/19
11/21
05:32
11/21/19
05:32
Hot Stocks
Cellcom Israel announces purported class action filed against the company »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

TPDKY

Topdanmark

$0.00

(0.00%)

05:31
11/21/19
11/21
05:31
11/21/19
05:31
Upgrade
Topdanmark rating change  »

Topdanmark upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOGL

Golden Ocean

$5.40

0.025 (0.47%)

05:31
11/21/19
11/21
05:31
11/21/19
05:31
Hot Stocks
Golden Ocean announces CEO resignation, chairman Ola Lorentzon named interim CEO »

Golden Ocean announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

05:30
11/21/19
11/21
05:30
11/21/19
05:30
General news
Bond markets erase gains, »

Bond markets erase gains,…

FLNG

Flex LNG

$9.40

0.74 (8.55%)

05:29
11/21/19
11/21
05:29
11/21/19
05:29
Downgrade
Flex LNG rating change  »

Flex LNG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCEXF

Saracen Mineral

$0.00

(0.00%)

05:28
11/21/19
11/21
05:28
11/21/19
05:28
Upgrade
Saracen Mineral rating change  »

Saracen Mineral upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWE

NorthWestern

$69.93

0.53 (0.76%)

05:26
11/21/19
11/21
05:26
11/21/19
05:26
Upgrade
NorthWestern rating change  »

NorthWestern upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$164.57

0.55 (0.34%)

05:23
11/21/19
11/21
05:23
11/21/19
05:23
Recommendations
Salesforce analyst commentary  »

Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 16

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.